CAS 108409-83-2: FH 535

FH535, a Wnt/β-catenin signaling and PPAR inhibitor, exhibits anti-tumor activities.

Applications Antagonizes Wnt/β-catenin/Tcf-mediated transcription as well as PPARγ and δ activity. Able to inhibit the recruitment of the co-activators β-catenin and GRIP1, both of which are activators for both pathways. References Handeli, S., et al.: Mol. Cancer Ther., 7, 521 (2008),

N-(2-Methyl-4-nitrophenyl)-2,5-dichlorobenzenesulfonamide (NMP) is an active analog of the antibiotic nitrofurantoin. It is a potent inhibitor of cellular RNA splicing and induces apoptosis in cancer cells. It also inhibits the synthesis of β-catenin protein and its signaling pathway, which regulates cell growth, differentiation, and survival. NMP has been shown to inhibit mineralization by inhibiting the expression of osteogenic protein genes such as those encoding osteopontin, bone sialoprotein I, and bone sialoprotein II.

FH535